Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The OxVent is a rapidly deployable and scalable low-cost mechanical ventilator specially designed for COVID-19, which has now been recognised as one of the best innovations of the year by the Institute of Engineering and Technology.

The Oxford ventilator

The ventilator project initially emerged as a response to the shortage of ventilators caused by the pandemic, with researchers from the University of Oxford and King’s College London working together in response to the UK Government’s ‘Ventilator Challenge’. The ventilator was shortlisted from among 5000 offers of support.

Subsequently, the exceptional team of engineers, medics and manufacturers partnered with Smith+Nephew to translate the academic prototype into a safe, reliable and manufacturable product. OxVent Ltd., the resulting joint-venture non-profit enterprise, will license the OxVent ventilator design for international deployment during the COVID-19 pandemic and beyond.

The E&T Innovation Awards (from the Institute of Engineering and Technology) recognise and celebrate the very best new innovations across the breadth of science, engineering and technology. The Awards give global recognition to those who are creating innovative and creative solutions, which are delivering a return.

OxVent won in the ‘Small Idea, Big Impact: Global Challenge’ category, beating five competing entries. OxVent fills the gap between expensive complex commercial ventilation systems and basic open-loop systems that lack sensors, feedback control or alarms. It provides the necessary level of performance for an emergency ventilator, yet with a scalable and affordable solution.

OxVent aims to become the global standard of care for low cost ventilators with a fully developed product range tailored to regional needs.

Professor Tim Denison, from the University of Oxford’s Department of Engineering Science and Nuffield Department of Clinical Neurosciences, said: ‘the success of OxVent was the unique partnership of an academic team who could challenge the status quo and a world-leading manufacturer of medical devices who could ensure quality and reliability. The mixture of backgrounds and perspectives allowed us to be both innovative and impactful.’

Professor Andrew Farmery, from the University of Oxford’s Nuffield Department of Clinical Neurosciences, said: ‘The pandemic stimulated us to think and design laterally, to create a device that was clinically credible, yet able to be built at speed and in volume, at times when supply chains are strained. This was a colossal team effort and we are very pleased to have been recognised in this way. OxVent is now a Social Enterprise company whose mission is to develop its catalogue to fulfil clinical need in low and middle income countries both now and beyond the pandemic'.

Professor Mark Thompson, from the University of Oxford’s Department of Engineering Science, said: 'This award is fantastic recognition for the exceptional team of PhD students, engineers, medics and manufacturers who brought their energy, commitment and technical skill to fulfil a humanitarian objective in the COVID-19 pandemic. This impulse continues to drive OxVent forward as a social enterprise delivering and supporting low cost ventilator technology in low and middle income countries.'

Similar stories

Accidental awareness in obstetric surgery under general anaesthesia more frequent than expected

Anaesthetics Research

The largest ever study of awareness during obstetric general anaesthesia shows around 1 in 250 women may be affected, and some may experience long-term psychological harm.

Developing diagnostics for COVID-19

Clinical Neurology Coronavirus Research

Associate Professor Sarosh Irani, who heads up our Autoimmune Neurology Group, has been funded by Mologic to help develop diagnostics for COVID-19.

COVID-19 and Guillain-Barré syndrome

Clinical Neurology Coronavirus Research

Multiple recent case reports have suggested a link between COVID-19 and Guillain-Barré syndrome (GBS), an acute, disabling, immune-mediated disorder of the peripheral nervous system. It is currently unclear whether this simply represents a chance association.

Viruses shown to evolve as a result of different immune responses in different ethnic populations

Clinical Neurology Coronavirus Research

New research into the HIV-1 virus has shed light on an important factor in the evolution of viruses, which is likely also to affect SARS-CoV-2 (the virus which causes COVID-19). This new insight could have important implications for vaccine development.

New NDCN Professors

Award

Congratulations to the five members of our Department who have been awarded the title of Professor in the recent round of the University’s Recognition of Distinction scheme.

Emerging Leaders Prize celebrates outstanding pain researchers

Award Clinical Neurology

2020’s Emerging Leaders Prize awards £200,000 to outstanding scientists from the University of Oxford, University College London and King’s College London, who are all working in the field of pain research.